Glycomimetics Inc (GLYC) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Exhibit 99.1

GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2015 RESULTS

ROCKVILLE, MD, February 29, 2016

For the quarter ended December 31, 2015, GlycoMimetics reported total revenues of $35,000. GlycoMimetics did not recognize any revenues in the quarter ended December 31, 2014.  For the year ended December 31, 2015, total revenues were $20.1 million compared to $15.0 million in 2014.

The company’s research and development expenses increased to $7.0 million for the quarter ended December 31, 2015 as compared to $5.3 million for the fourth quarter of 2014.  Research and development expense similarly increased by $5.5 million to $25.1 million for the year ended December 31, 2015, from $19.6 million in the year ended December 31, 2014. These increases were primarily attributable to increased costs associated with the Phase 1/2 clinical trial with GMI-1271 and pre-clinical development of GMI-1359, the company’s next drug candidate.  In addition, GlycoMimetics recorded a $2.0 million milestone license fee in the year ended December 31, 2015 for the payment due to the University of Basel representing 10 percent of the $20.0 million non-refundable milestone payment received from Pfizer in August 2015.

The company’s general and administrative expenses decreased to $1.9 million for the quarter ended December 31, 2015 as compared to $2.1 million for the fourth quarter of 2014.  General and administrative expenses for the year ended December 31, 2015 increased to $7.8 million as compared to $6.6 million in the prior year.  These increases were primarily due to increased professional fees as well as stock-based compensation expense.

“In 2015, we made significant progress in clinical development both with our partnered, lead drug candidate rivipansel and with the proprietary programs in our pipeline. Importantly, our partner Pfizer initiated the Phase 3 trial of rivipansel for the treatment of vaso-occlusive crisis. In parallel, we were able to progress our proprietary oncology pipeline, most notably, GMI-1271, for acute myeloid leukemia (AML) and other blood disorders. For GMI-1271, we were able to present encouraging data at the 2015 ASH meeting in December as well as advance the drug in a dose-ranging trial in patients, for which we expect to have data to report in the second quarter of this year,” said Rachel King, GlycoMimetics’ Chief Executive Officer.

“Our plan for the rest of 2016 is to continue to advance our two lead programs as well as to initiate clinical trials of a third product candidate, GMI-1359. Among our highest priorities are presentations to the medical communities of key data and potential therapeutic opportunities made possible by our proprietary selectin-directed clinical and preclinical programs,” Ms. King added.